What is AVS?
Founded in 2017 by Dr. Hitinder Gurm and Dr. Robert Chisena, AVS is at the forefront of redefining interventional therapy for calcified arterial disease. The company's proprietary Pulse IVL system offers a revolutionary approach to intravascular lithotripsy, transforming how physicians address severely calcified lesions. AVS operates within the dynamic medical device sector, focusing on creating safer and more effective treatment modalities for a critical cardiovascular condition. The company's commitment to innovation positions it as a key player in the fight against arterial disease.
How much funding has AVS raised?
AVS has raised a total of $64.8M across 3 funding rounds:
Series B
$20M
Series B
$8.8M
Series B
$36M
Series B (2023): $20M with participation from BioStar Capital
Series B (2023): $8.8M led by BioStar Capital
Series B (2025): $36M supported by BioStar Capital and CUE Growth Partners
Key Investors in AVS
BioStar Capital
BioStar Capital is a visionary healthcare investor focused on transformative medical devices. The company combines business acumen with clinical expertise, leveraging a collaboration of healthcare clinicians, medical thought leaders, and financial professionals. With over two decades of experience, BioStar Capital is dedicated to producing life-changing outcomes for patients while delivering rewarding returns for investors. Their portfolio showcases innovations that have a significant impact on the medical technology landscape.
CUE Growth Partners
Cue Growth Partners is a Growth Equity firm based in New York that specializes in providing flexible capital at the intersection of venture capital and private equity. The firm focuses on transformational healthcare capital, investing in areas such as medical technology and healthcare services. With a unique investment approach, Cue Growth Partners aims to accelerate human clinical trials and facilitate strategic relationships to support company growth initiatives. Their extensive network includes relationships with physicians, health systems, and regulatory experts, allowing them to deliver differentiated insights and outcomes in the healthcare sector.
BioStar Capital
BioStar Capital invests in and nurtures transformative medical technologies. Their team of renowned healthcare clinicians and executives, medical thought leaders, and financial professionals brings unique insight to every investment opportunity. By marshaling a rare combination of domain expertise, industry connections, and access to medical facilities and innovators, BioStar Capital has consistently produced life-changing outcomes for patients and rewarding returns for investors.
What's next for AVS?
With its recent Series B financing, AVS is poised for significant expansion and market leadership. The substantial capital raised, including the major strategic investment, will likely fuel further research and development, enhance manufacturing capabilities, and broaden its commercial reach. The company's focus on a niche yet critical area of cardiovascular intervention suggests a strategic roadmap aimed at capturing a significant share of the interventional cardiology market. Future growth may involve expanding the clinical applications of the Pulse IVL system and forging new strategic partnerships within the healthcare ecosystem.
See full AVS company page
